Drugs.com
OCTOBER 6, 2024
SUNDAY, Oct. 6, 2024 — Pain, tingling and cramps in your legs and feet may be giving you a warning.They could be signs of poor blood circulation, which can lead to serious heart and health problems if left untreated, according to a doctor at Baylor.
Chemical Biology and Drug Design
OCTOBER 6, 2024
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disorder characterized by loss of memory and other cognitive functions. The problem of this disease is even more fundamental because the available therapies only provide symptomatic relief without addressing the basic factor of the disease. This review article comprehensively summarized the recent advancement in memantine and its hybrid analogs as potential disease-modifying agents for the management of AD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
OCTOBER 6, 2024
NUCYNTA ER (tapentadol hydrochloride) Collegium pharm inc Patent: 8,114,383 Expiration: Oct 10, 2024 See More … Source
Common Sense for Drug Policy Blog
OCTOBER 6, 2024
Marijuana, Psychosis, and Policy Development "Two things are needed to move beyond policy-biased appraisals of the evidence on cannabis and psychosis. "First, we need to use explicit criteria to assess the evidence for contributory causal relationships and apply them in an even-handed and consistent way. We should avoid the example of the tobacco industry in setting such a high standard of evidence for a causal inference that no evidence can satisfy it ( 30 ).
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
SugarCone Biotech
OCTOBER 6, 2024
By Paul D. Rennert, SugarCone Biotech LLC. Cell surface degraders are weird but cool. There is an emerging class of therapeutics, brilliant really, that make use of cell surface proteins that will respond to antibody binding by moving quickly inside the cell and then shuttling over to lysosomes for degradation. The trick is bind to these “internalizer proteins” with a bispecific antibody or fusion protein so they drag a second bound targeted protein with them.
Expert insights. Personalized for you.
264 
Let's personalize your content